Duane - your time has come

Duane - grow a pair and deal with the chaos you created.
Until then - here are your FAQs from sales:

Is the field mad at me?
Yes
Will they still be mad at me if they keep their jobs?
Yes
Will they ever respect me as a leader again?
No
Did they ever respect me at all?
Probably not
Should I take accountability for my massive F up?
Yes
Does everyone think I’m a liar?
Yes

well said
 




Fighting Entresto generics
In September, Novartis sent the FDA a petition, after a similar one was rejected in April 2021, asking for Entresto’s patent protection to be extended to February 2024. Novartis argued that the early release of Entresto generics could cause labelling inconsistencies. At least 18 generics companies, including Teva Pharmaceutical, Viatris and Lupin Pharmaceuticals, are preparing to release their Entresto generics in July 2023 when the FDA will remove its last regulatory stay blocking generic approvals. In October, Novartis sued Viatris subsidiary Mylan plus Alembic, Crystal Pharmaceutical, MSN Pharmaceuticals and Nanjing Noratech for patent infringement surrounding Novartis’ ‘918 patent on Entresto.
 




So what does this mean?

Fighting Entresto generics
In September, Novartis sent the FDA a petition, after a similar one was rejected in April 2021, asking for Entresto’s patent protection to be extended to February 2024. Novartis argued that the early release of Entresto generics could cause labelling inconsistencies. At least 18 generics companies, including Teva Pharmaceutical, Viatris and Lupin Pharmaceuticals, are preparing to release their Entresto generics in July 2023 when the FDA will remove its last regulatory stay blocking generic approvals. In October, Novartis sued Viatris subsidiary Mylan plus Alembic, Crystal Pharmaceutical, MSN Pharmaceuticals and Nanjing Noratech for patent infringement surrounding Novartis’ ‘918 patent on Entresto.
 




What this means is that if Novartis lawyers can’t fight Entresto’s loss of exclusivity then we could see a generic Entresto hit the market in July 2023. I would have to think that is part of the reason why we will not know our fate until the end of April. If the lawyers loose the lawsuit then that would give management its 90 day WARN period (April, May, June), to cover its corporate, legal obligation and would also mean a major blood letting of the sales force.
 




What this means is that if Novartis lawyers can’t fight Entresto’s loss of exclusivity then we could see a generic Entresto hit the market in July 2023. I would have to think that is part of the reason why we will not know our fate until the end of April. If the lawyers loose the lawsuit then that would give management its 90 day WARN period (April, May, June), to cover its corporate, legal obligation and would also mean a major blood letting of the sales force.
 




What this means is that if Novartis lawyers can’t fight Entresto’s loss of exclusivity then we could see a generic Entresto hit the market in July 2023. I would have to think that is part of the reason why we will not know our fate until the end of April. If the lawyers loose the lawsuit then that would give management its 90 day WARN period (April, May, June), to cover its corporate, legal obligation and would also mean a major blood letting of the sales force.[/

Appreciate the logical post…which direction does the case seem to be going?
 




I dont believe our waiting till April has anything to do with Entresto case. Right now are correcting Duane’s massive miscalculation on expanding pcp. When Entresto goes, they will do a massive layoff. Much larger than this one.

ZS Assoc prob creating maps for now and another mapping structure for when Entresto goes.
 




I dont believe our waiting till April has anything to do with Entresto case. Right now are correcting Duane’s massive miscalculation on expanding pcp. When Entresto goes, they will do a massive layoff. Much larger than this one.

ZS Assoc prob creating maps for now and another mapping structure for when Entresto goes.
I’m pretty sure we are paying for laughing at him at the fireside chat. He won’t go, we will go.
 




I’m pretty sure we are paying for laughing at him at the fireside chat. He won’t go, we will go.

He will go eventually because he doesn't have the vision or ability to right the ship. None of these changes will make any difference unless you change the leadership and direction from the top. He may not go before many of us but Novartis will dump him at some point. Frankly, I don know if I've ever encountered a worse leader of people with no vision or public speaking skills
 




Most people saw this disaster coming before we even launched Leqvio, at least on the rep level. It's astounding that the people at the top either were too obtuse to know the market dynamics in cardiology and that the launch strategy didn't mesh up with the market, or didn't have the guts to call somebody's baby ugly. Eventually everyone at the top will get cleared out. Happened with Entresto so would expect Leqvio to go the same way
 




Most people saw this disaster coming before we even launched Leqvio, at least on the rep level. It's astounding that the people at the top either were too obtuse to know the market dynamics in cardiology and that the launch strategy didn't mesh up with the market, or didn't have the guts to call somebody's baby ugly. Eventually everyone at the top will get cleared out. Happened with Entresto so would expect Leqvio to go the same way

Sure. But at what cost? How many of us in the field have to suffer before the source of the problem is removed? It’s the same scenario over and over again. Your issue starts at the top. Remove the source, and stop having others below bear the brunt of their mistake. Too many of these individuals leave a path of destruction behind them before they are finally held accountable. It’s repulsive.
 












Novartis leadership (including MANY ABL's) are disgusting, feckless, and timidly weak minions who thrive in the cesspool of foolhardy decisions made since Leqvio launch. The extraordinary top heavy infrastructure of personnel hired to promote this 'me too' drug is preposterous...adding to the outrageous cost of acquisition. "Leqvio has to succeed" is the mantra. Fuck you...should have worked the calculator a few more times before paying almost 10 bil. for a mediocre injection you can't figure out how to sell, or pay reps that do. Oh, good idea Duane for hiring hundreds of PCP reps during Covid who now will lose their jobs. Fuck you Duane, and every other self described 'leader' at Novartis. You're all a joke, with no one laughing.
 




Novartis leadership (including MANY ABL's) are disgusting, feckless, and timidly weak minions who thrive in the cesspool of foolhardy decisions made since Leqvio launch. The extraordinary top heavy infrastructure of personnel hired to promote this 'me too' drug is preposterous...adding to the outrageous cost of acquisition. "Leqvio has to succeed" is the mantra. Fuck you...should have worked the calculator a few more times before paying almost 10 bil. for a mediocre injection you can't figure out how to sell, or pay reps that do. Oh, good idea Duane for hiring hundreds of PCP reps during Covid who now will lose their jobs. Fuck you Duane, and every other self described 'leader' at Novartis. You're all a joke, with no one laughing.
I can sell anything if I’m paid well to do it, but I have not been paid well to do it for the last year. Instead Novartis spends all their money on the management level to slow me down with useless meetings and demotivate me with micromanagement.
 




I can sell anything if I’m paid well to do it, but I have not been paid well to do it for the last year. Instead Novartis spends all their money on the management level to slow me down with useless meetings and demotivate me with micromanagement.
Agree completely. It’s like being in kindergarten in CRM
 




Does anyone have any idea what percentage headcount reduction we are looking at for CV? PCP is being migrated to CV before or after? I know they are only losing one RD. With that I would thing less than 10%. What do y’all think?

Pure speculation, but if they’re going from 2 CV and 2 PCP per territory down to 2 CV, that’s a 50% cut. They’re saying “but territories are getting smaller so they’ll be more of them”. Well they’re not going to double the number territories! So let’s say at least 30% cut. The losing 1 region means nothing because that doesn’t create more territories, it just puts more geography under each region, but the size of the country doesn’t change! Plus, prior to PCP team being added on, CV’s called on both cards and PCP, and my territory was the EXACT same as it is now, so how much smaller are they really making the territories? I’d say not much or not at all. Duane is basically reverting things back to exactly how they were before he came in and fucked it all up. Side note: hilarious how they said “we are listening to HCP feedback and this is what they are telling us”. Oh really Duane? Who the hell are these HCP’s that you’re getting ahold of on the phone or wherever, and then they’re just saying, “How the hell are you Diane! Sure, I’ll give you some advice on how to structure a pharma company, I have time to chat”. Really? Lol. Yes, all the doctors provided feedback to Novartis and Novartis is just “doing what the customer wants”. Right. Get one on the phone right now. Just one
 




Pure speculation, but if they’re going from 2 CV and 2 PCP per territory down to 2 CV, that’s a 50% cut. They’re saying “but territories are getting smaller so they’ll be more of them”. Well they’re not going to double the number territories! So let’s say at least 30% cut. The losing 1 region means nothing because that doesn’t create more territories, it just puts more geography under each region, but the size of the country doesn’t change! Plus, prior to PCP team being added on, CV’s called on both cards and PCP, and my territory was the EXACT same as it is now, so how much smaller are they really making the territories? I’d say not much or not at all. Duane is basically reverting things back to exactly how they were before he came in and fucked it all up. Side note: hilarious how they said “we are listening to HCP feedback and this is what they are telling us”. Oh really Duane? Who the hell are these HCP’s that you’re getting ahold of on the phone or wherever, and then they’re just saying, “How the hell are you Diane! Sure, I’ll give you some advice on how to structure a pharma company, I have time to chat”. Really? Lol. Yes, all the doctors provided feedback to Novartis and Novartis is just “doing what the customer wants”. Right. Get one on the phone right now. Just one
 




Better yet, prove it.

Duane, show your cell records proving that you were able to virtually engage an HCP who provided this feedback.

Rather, Patrick is so prominent on the leadership panel that I'm sure his team came back and demanded elimination of the ADSOCs. Redundant, yes, but I'm not so sure listening to a biased Patrick was the right move. A thoughtful approach to deploying a cohesive team of collaborators would be the better move but not Novartis. Cut 'em! So predictable
 




The decision to cut adsoc came after cv meeting in Dallas. The “ISET” team leaders did not perform & didn’t come close to producing what they said they would.
They’ve protected for years at director level pay. Between ABls, ISS, Adsar, FRMs and reps they didn’t have 100% ownership of any specific roll.